Utility of midpoint imaging in patients receiving peptide receptor radionuclide therapy (PRRT) for advanced progressive midgut neuroendocrine tumors (NET)

被引：0
|
作者：
Norman, A. [1 ]
Wee, C. [1 ]
Hobday, T. [1 ]
Kendi, A. [1 ]
Johnson, G. [1 ]
Thorpe, M. [1 ]
Lunn, B. [1 ]
Bach, C. [1 ]
Eiring, R. [1 ]
Halfdanarson, T. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2021年 / 33卷
关键词：
midpoint imaging; prrt; clinical decision making;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K25
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [1] Utility of Midpoint Imaging in Patients Receiving Peptide Receptor Radionuclide Therapy (PRRT) for Advance Progressive Gastroenteropancreatic-Neuroendocrine Tumors (GEP-NETs)
    Norman, Aurora P.
    Wee, Christopher
    Hobday, Timothy J.
    Kendi, Ayse T.
    Johnson, Geoffrey B.
    Thorpe, Matthew P.
    Lunn, Brendan W.
    Bach, Corrie R.
    Halfdanarson, Thorvardur R.
    PANCREAS, 2022, 51 (03) : E45 - E45
  • [2] Clonal Hematopoiesis in Patients with Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy (PRRT)
    Singh, Abhay
    Gravina, Matthew
    Tajammal, Rutaba
    Nowak, Annmarie
    Iyer, Renuka
    Faber, Mark G.
    Yan, LunBiao
    Hassane, Duane C.
    Guzman, Monica L.
    Mencia-Trinchant, Nuria
    Wang, Eunice S.
    Thota, Swapna
    BLOOD, 2020, 136
  • [3] Peptide receptor radionuclide therapy (PRRT) of midgut neuroendocrine tumors: assessment of quality of life
    Marinova, Milka
    Muecke, Martin
    Fischer, Felix
    Essler, Markus
    Cuhls, Henning
    Radbruch, Lukas
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [4] Evaluation of toxicity in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET)
    Duan, H.
    Ferri, V.
    Kunz, P. L.
    Fisher, G. A.
    Moradi, F.
    Davidzon, G. A.
    Franc, B. L.
    Iagaru, A. H.
    Mari, C. Aparici
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S471 - S472
  • [5] Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)
    Duan, H.
    Girod, B.
    Ninatti, G.
    Ferri, V
    Kunz, P.
    Fisher, G.
    Moradi, F.
    Davidzon, G.
    Franc, B.
    Lagaru, A.
    Aparici, Mari C.
    NEUROENDOCRINOLOGY, 2020, 110 : 252 - 252
  • [6] Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
    Duan, H.
    Ninatti, G.
    Girod, B.
    Ferri, V
    Guja, K.
    Song, H.
    Kunz, P.
    Fisher, G.
    Lagaru, A.
    Mari, Aparici C.
    NEUROENDOCRINOLOGY, 2020, 110 : 253 - 253
  • [7] Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET)
    Duan, Heying
    Ninatti, Gaia
    Girod, Bradley
    Ferri, Valentina
    Kunz, Pamela L.
    Fisher, George A.
    Moradi, Farshad
    Davidzon, Guido Alejandro
    Franc, Benjamin Lewis
    Iagaru, Andrei
    Mari, Carina
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [8] Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
    Duan, H.
    Ferri, V.
    Kunz, P.
    Davidzon, G.
    Nguyen, J.
    Moradi, F.
    Franc, B.
    Iagaru, A.
    Aparici, C. Mari
    PANCREAS, 2021, 50 (03) : 456 - 456
  • [9] Safety in Patients With Neuroendocrine Tumors Receiving Telotristat Ethyl (TE) With Peptide Receptor Radionuclide Therapy (PRRT)
    Chauhan, A.
    Binder, P.
    Tesfaye, E.
    Seth, K.
    Lapuerta, P.
    PANCREAS, 2021, 50 (03) : 447 - 448
  • [10] Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A single institution experience in the USA
    Duan, H.
    Ferri, V.
    Kunz, P. L.
    Fisher, G. A.
    Moradi, F.
    Davidzon, G. A.
    Franc, B. L.
    Iagaru, A. H.
    Mari, C. Aparici
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S468 - S469
12345